AIM： To investigate the prognostic significance of phosphatase regenerating liver 3 （PRL-3） protein expression in gastric cancer.METHODS： PRL-3 expression in paraffin-embedded tumor specimens from 293 patients wit...AIM： To investigate the prognostic significance of phosphatase regenerating liver 3 （PRL-3） protein expression in gastric cancer.METHODS： PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Nonoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique.RESULTS： Positive PRL-3 expression was detected in 43.3% （227 of 293） of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression （28.3% vs 52.9%, P 〈 0.0001）. Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression （hazard ratio of 16.7 and 16.6, respectively; P 〈 0.0001 for both）. Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage Ⅲ patients. CONCLUSION： PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection,展开更多
We aimed to investigate risk factors of local and distant recurrence in small-sized, node negative breast cancer in women 〈35 years in a Chinese cohort. Between January 1994 and January 2007, 107 patients with pathol...We aimed to investigate risk factors of local and distant recurrence in small-sized, node negative breast cancer in women 〈35 years in a Chinese cohort. Between January 1994 and January 2007, 107 patients with pathologically confirmed small-sized （E1 cm）, node negative breast cancer who did not receive neoadjuvant or adjuvant chemotherapy were included. The 5-year recurrence-free survival （RFS） was estimated according to different prognostic variables. With a median time of 60 months （range, 8-60 months） follow-up, local and distant recurrence were observed in 25 cases （23.4%）. By univariate analysis, HER-2 positivity, triple negative （TN）, and high Ki-67 index （~14%） were risk factors of a lower RFS （hazard ratio （HR） 6.680, 95% confidence interval （CI） 2.350-18.985, P〈0.0001 for HER-2 positive; HR 4.769, 95%CI 1.559-14.591, P=0.006 for TN; HR 6.030, 95%CI 2.659-13.674, P〈0.0001 for high Ki-67 index）. Patients with grade 3 tumors had a lower RFS （HR 2.922, 95%CI 1.096-7.791, P=0.032） compared with those with grade 1 or grade 2 tumors. By multivariate analysis, HER-2 positivity （HR 10.204, 95%CI 3.391-30.704, P〈0.0001）, TN （HR 10.521, 95% CI 3.152-35.113, P〈0.0001） and high Ki-67 index （HR 10.820, 95%CI 4.338-27.002, P〈0.0001） remained risk factors of RFS. In this cohort, HER-2 positivity, triple neg- ative and high Ki-67 index were independent risk factors of RFS in young patients with Tla,bN0 breast cancer. Subsequent pregnancy did not affect RFS.展开更多
基金Supported by Grant for Key Technology Research and Development Program 2002BA711A06National Basic Research Priorities Program 973 Project 1998051203the Ministry of Science and Technology of China,and grant H020920030390,from the Beijing Science and Technology Commission
文摘AIM： To investigate the prognostic significance of phosphatase regenerating liver 3 （PRL-3） protein expression in gastric cancer.METHODS： PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Nonoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique.RESULTS： Positive PRL-3 expression was detected in 43.3% （227 of 293） of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression （28.3% vs 52.9%, P 〈 0.0001）. Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression （hazard ratio of 16.7 and 16.6, respectively; P 〈 0.0001 for both）. Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage Ⅲ patients. CONCLUSION： PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection,
文摘We aimed to investigate risk factors of local and distant recurrence in small-sized, node negative breast cancer in women 〈35 years in a Chinese cohort. Between January 1994 and January 2007, 107 patients with pathologically confirmed small-sized （E1 cm）, node negative breast cancer who did not receive neoadjuvant or adjuvant chemotherapy were included. The 5-year recurrence-free survival （RFS） was estimated according to different prognostic variables. With a median time of 60 months （range, 8-60 months） follow-up, local and distant recurrence were observed in 25 cases （23.4%）. By univariate analysis, HER-2 positivity, triple negative （TN）, and high Ki-67 index （~14%） were risk factors of a lower RFS （hazard ratio （HR） 6.680, 95% confidence interval （CI） 2.350-18.985, P〈0.0001 for HER-2 positive; HR 4.769, 95%CI 1.559-14.591, P=0.006 for TN; HR 6.030, 95%CI 2.659-13.674, P〈0.0001 for high Ki-67 index）. Patients with grade 3 tumors had a lower RFS （HR 2.922, 95%CI 1.096-7.791, P=0.032） compared with those with grade 1 or grade 2 tumors. By multivariate analysis, HER-2 positivity （HR 10.204, 95%CI 3.391-30.704, P〈0.0001）, TN （HR 10.521, 95% CI 3.152-35.113, P〈0.0001） and high Ki-67 index （HR 10.820, 95%CI 4.338-27.002, P〈0.0001） remained risk factors of RFS. In this cohort, HER-2 positivity, triple neg- ative and high Ki-67 index were independent risk factors of RFS in young patients with Tla,bN0 breast cancer. Subsequent pregnancy did not affect RFS.
